LY305
LY305 is a transdermally bioavailable selective androgen receptor modulator (SARM) developed by Eli Lilly for the treatment of osteoporosis Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural deterioration of bone tissue leading to more porous bone, and consequent increase in Bone fracture, fracture risk. It is the most common reason f ... in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD, Narayanan R. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer. ''Int J Mol Sci''. 2021 Feb 20;22(4):2124. See also * Compound 2f (SARM) References {{reflist Selective androgen receptor modulators Chloroarenes Anilines Nitriles Cyclopentanols Benzonitriles ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]